Sigma Healthcare Ltd · ASX:SIG

Sigma Healthcare — H1 2025 Earnings Presentation

24 slides from Sigma Healthcare's earnings presentation, Feb 27, 2025

  1. Slide 1: Roadshow Presentation

    Roadshow Presentation Sigma Healthcare Limited ABN 15 088 417 403 For personal use only Presenters: For more information contact: Vikesh Ramsunder Gary Woodford CEO & Managing Director Head of Corporate Affairs gary.woodford@sigmahealthcare.com.au Mark Davis www.sigmahealthcare.com.au CFO

  2. Slide 2: Key Investment Highlights

    Key Investment Highlights Australia’s largest retail pharmacy franchisor1 underpinned by 20 years of consistent growth2 in Chemist Warehouse Retail Network For personal use only Merger combines proven retailing strengths with highly efficient supply chain capabilities to support ongoing network expa

  3. Slide 3: Snapshot of the Merged Group

    Snapshot of the Merged Group The Merged Group is a leading Australian retail pharmacy franchisor and a full-line pharmaceutical wholesaler and distributor For personal use only Operational highlights Financial highlights 879 81 $9.6bn +10% Australian Franchise International stores LTM Dec-24 CW LFL

  4. Slide 4: Chemist Warehouse's Growth Track Record

    Chemist Warehouse’s Growth Track Record 20 years of consecutive growth in Chemist Warehouse Retail Network For personal use only CW Retail Network Sales evolution ($m)1,2,3 CW Retail Network evolution (no. of stores)1,4 10 year avg. new 5 year avg. new 10 year CAGR: 5 year CAGR: stores p.a.: stores

  5. Slide 5: Benefits of the Merger

    Benefits of the Merger  Cross-application of Chemist Warehouse marketing and media capabilities For personal use only Retail expertise  Extend value-added franchise services to Amcal and DDS brand platforms  Expansion of private label and exclusive brands Lower distribution costs and deepen exist

  6. Slide 6: The Merged Group's Competitive Strengths

    The Merged Group’s Competitive Strengths Complementary capabilities: combines highly efficient supply chain with 15 For personal use only  proven retail expertise to deliver exceptional value and enable growth Distribution centres across ANZ1 Market leading franchise model: delivers strong outcomes

  7. Slide 7: Complementary Franchise Brands Across Broad Market Segments

    Complementary Franchise Brands Across Broad Market Segments For personal use only Big box • 527 stores in Australia2 • Significant Australian pharmacy brand with franchise pharmacies known for offering a wide discount range of FOS products, and everyday low prices on all product lines1 • 522 sqm avg

  8. Slide 8: Differentiated Chemist Warehouse Retail Offering

    Differentiated Chemist Warehouse Retail Offering Iconic and well recognised brand in Australia Extensive FOS offering For personal use only Chemist Warehouse has established itself as a highly recognisable brand amongst Chemist Warehouse stores display a breadth and range of stock not commonly consu

  9. Slide 9: Case Study: Messi Fragrance Launch

    Case Study: Messi Fragrance Launch “More than we see” Australian expertise, ingenuity and know-how trusted to deliver a global success story For personal use only ● Through its GameOn subsidiary, CWG wins a 2022/23 global pitch for the exclusive licence to develop the Messi fragrance range ● CWG int

  10. Slide 10: Growth Pillar: Domestic Store Rollout

    Growth Pillar 1 Domestic Store Rollout Current Australian Retail Network1 Growth opportunity For personal use only CW has a proven track record of sustained strong domestic growth Under penetration in certain states provides organic growth opportunities Opportunity to expand Amcal and DDS network th

  11. Slide 11: Growth Pillar: International Store Rollout

    Growth Pillar 2 International Store Rollout International Store Network1 Growth opportunity For personal use only Total # Registered CW International Store Network Pharmacies The NZ experience demonstrates the transportability and acceptance of the Chemist Warehouse brand and value proposition in ne

  12. Slide 12: Growth Pillar: Supply Chain Capabilities Drive Scale and Efficiency

    Growth Pillar 3 Supply Chain Capabilities Drive Scale and Efficiency Comprehensive DC network in Australia1 Network optimisation For personal use only 272k Optimise capacity and throughput at warehouses Aggregate capacity (sqm) of 14 DCs in Australia1 Enhance distribution efficiencies and remove dup

  13. Slide 13: Providing Superior Outcomes for Consumers, Franchisees and Supplier Partners

    Growth Pillar 4 Providing Superior Outcomes for Consumers, Franchisees and Supplier Partners Consumers For personal use only Expand range of owned, private label A and exclusive brands and products B Grow online penetration / omni-channel  Greater choice  Margin driver  Convenience $821m 3m 16% C

  14. Slide 14: Financial Information

    Financial Information For personal use only

  15. Slide 15: Approach to Sigma's Future Financial Reporting

    Approach to Sigma’s Future Financial Reporting Accounting for the Transaction Near term future financial reporting For personal use only CWG standalone results Sigma FY25 results Legal acquiror 6 months to 31-Dec-24 12 months to 30-Jun-25 12 months of CWG financial Presented today information and Si

  16. Slide 16: CWG Standalone 1H25 Results Highlights

    CWG Standalone 1H25 Results Highlights Sustained growth through new franchise store openings, international expansion, strong Like-for-Like sales growth and new supply agreements also benefitting margins For personal use only Financial Performance 1H25 Commentary Growth vs. 1H FY25 1H FY24 Strong ea

  17. Slide 17: CWG Standalone 1H25 Statutory Results

    CWG Standalone 1H25 Statutory Results Statutory Profit & Loss – No normalisation adjustments $’000 1H FY25 1H FY24 Commentary For personal use only Total Revenue 1,963,661 1,771,244 • Financials for CWG represent statutory results before any normalisations or Gross Profit 677,302 556,007 management

  18. Slide 18: Sigma Standalone FY25 Trading Update

    Sigma Standalone FY25 Trading Update • Upgraded Sigma standalone full year normalised EBIT guidance of $64 – 70m for the year ending 31 January 2025 For personal use only — Up from $50 – 60m range previously guided in September 2024 • Upgrade driven by improved operational performance — Strong execu

  19. Slide 19: Board & Governance

    For personal use only Board & Governance

  20. Slide 20: Board of Directors

    Board of Directors For personal use only Michael Sammells Vikesh Ramsunder Dr Christopher (Chris) Roberts AO Annette Carey Neville Mitchell Independent Non-Executive Chief Executive Officer & Independent Independent Independent Chairman Managing Director Non-Executive Director Non-Executive Director

  21. Slide 21: Related Party Governance Framework

    Related Party Governance Framework For personal use only • Negotiate and enter into Future Related Party Dealings • Renew and amend Existing Related Party Arrangements Related Party and Future Related Party Dealings Independent Board • Ensure that, at all times, the Existing Related Party Committee

  22. Slide 22: Outlook

    For personal use only Outlook

  23. Slide 23: Outlook

    Outlook For personal use only • Continued momentum in Retail Network sales driven by strong customer value proposition and new store openings in both the domestic and international markets • Extract efficiencies in the distribution network through a number of initiatives, including: — Optimising inv

  24. Slide 24: Thank you

    For personal use only Thank you

Sigma Healthcare — H1 2025 Earnings Presentation on 6ix